Atezolizumab/bevacizumab/lenvatinibImmune‑related hypopituitarism, primary hypothyroidism and no response: 3 case reports

被引：0

作者：

机构：

来源：

Reactions Weekly | 2023年 / 1961卷 / 1期

关键词：

D O I：

10.1007/s40278-023-41333-x

中图分类号：

学科分类号：

摘要：

引用

页码：76 / 76

共 50 条

[41] CabozantinibDiarrhoea, hypothyroidism and rash: 3 case reports
Reactions Weekly, 2025, 2051 (1) : 72 - 72
[42] NivolumabLichen planus and hypothyroidism: 3 case reports
Reactions Weekly, 2018, 1711 (1) : 223 - 223
[43] A case of hepatocellular carcinoma with “pseudoprogression” followed by complete response to atezolizumab plus bevacizumab
Naoshi Odagiri
Akihiro Tamori
Kohei Kotani
Hiroyuki Motoyama
Etsushi Kawamura
Atsushi Hagihara
Hideki Fujii
Sawako Uchida‑Kobayashi
Masaru Enomoto
Norifumi Kawada
Clinical Journal of Gastroenterology, 2023, 16 : 392 - 396
[44] Bevacizumab/doxorubicinMyelosuppression and hypertension: 3 case reports
Reactions Weekly, 2022, 1888 (1) : 103 - 103
[45] Bevacizumab/fluorouracilOral mucositis: 3 case reports
Reactions Weekly, 2011, 1370 (1) : 11 - 11
[46] Bevacizumab/cetuximabPulmonary toxicities: 3 case reports
Reactions Weekly, 2021, 1868 (1) : 113 - 113
[47] Bevacizumab/ifosfamide/sorafenibNeurotoxicity: 3 case reports
Reactions Weekly, 2012, 1409 (1) : 15 - 15
[48] Bevacizumab/dexamethasoneVarious toxicities: 3 case reports
Reactions Weekly, 2018, 1713 (1) : 64 - 64
[49] A case of hepatocellular carcinoma with "pseudoprogression" followed by complete response to atezolizumab plus bevacizumab
Odagiri, Naoshi
Tamori, Akihiro
Kotani, Kohei
Motoyama, Hiroyuki
Kawamura, Etsushi
Hagihara, Atsushi
Fujii, Hideki
Uchida-Kobayashi, Sawako
Enomoto, Masaru
Kawada, Norifumi
CLINICAL JOURNAL OF GASTROENTEROLOGY, 2023, 16 (03) : 392 - 396
[50] Bevacizumab/perflutrenAcute endophthalmitis: 3 case reports
Reactions Weekly, 2014, 1521 (1) : 45 - 45

← 1 2 3 4 5 →